NIKKEI 225
38,332.66 +130.29 (+0.34%) HANG SENG
18,538.57 +224.71 (+1.23%) CRUDE OIL
79.41 +0.42 (+0.53%) GOLD FUTURES
2,320.10 -2.20 (-0.09%) DOW
39,056.39 +172.13 (+0.44%) Bitcoin GBP
49,317.57 -1,081.32 (-2.15%)
Inhibrx, Inc. (INBX)
After hours:
- PR Newswire
Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger
Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") today announced that it has set a record date of May 17, 2024 (the "Record Date") for the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. ("SpinCo"), to holders of shares of the Company's common stock on a pro rata basis (the "Spin-Off").
- Zacks
Inhibrx, Inc. (INBX) Reports Q4 Loss, Tops Revenue Estimates
Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of -61.68% and 1,534%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results
Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a biopharmaceutical company with three clinical programs in development and a strong emerging pipeline, today reported financial results for the fourth quarter and fiscal year 2023.
